Cartesian Therapeutics (RNAC) Stock Price, Quote, News & History | Benzinga

Cartesian Therapeutics Inc (RNAC) Stock Price, Quote, News & History

RNACNASDAQ

Trade with Public

Trade with Public

$8.84

0.121.38%

At close: Aug 14, 5:00 PM EST

$8.72

-0.12-1.36%

After Hours: Aug 13, 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$8.77

Close

$8.84

Volume / Avg.

86.40K / 259.96K

Day Range

$8.50 - $8.96

52 Wk Range

5.60 - 12.25

Market Cap

$263.83M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

13.29%

Days to Cover

14.89

Recent Cartesian Therapeutics, Inc. News

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.

Vandana Singh

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.

Vandana Singh

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.

Vandana Singh

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-76.53M

Investing Cash Flow (TTM)

-2.08M

Financing Cash Flow (TTM)

65.93M

Free Cash Flow (TTM)

-78.61M

Capital Expenditure (TTM)

-2.08M

Net Change in Cash (TTM)

-12.69M

Analyst Trends and Forecast

3

Mar

4

May

3

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$183.40M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

160.02

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-66.21%

Earnings Yield % (FWD)

-34.94%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$4.14

Company Debt

Total Debt

$52.85M

LT Debt

$52.85M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$147.61M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$8.77

Close

$8.84

Volume / Avg.

86.40K / 259.96K

Day Range

$8.50 - $8.96

52 Wk Range

5.60 - 12.25

Market Cap

$263.83M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

57

Short Interest

13.29%

Days to Cover

14.89

About

Sector

Health Care

Industry

Biotechnology

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cartesian Therapeutics (RNAC) stock?

A

You can purchase shares of Cartesian Therapeutics (NASDAQ:RNAC) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cartesian Therapeutics (RNAC) competitors?

A

Other companies in Cartesian Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Cartesian Therapeutics (RNAC) stock?

A

Cartesian Therapeutics has a consensus price target of $36.11.

Q

What is the current price for Cartesian Therapeutics (RNAC)?

A

The stock price for Cartesian Therapeutics (NASDAQ: RNAC) is $8.72 last updated August 13, 2026 at 4:00 PM EDT.

Q

Does Cartesian Therapeutics (RNAC) pay a dividend?

A

There are no upcoming dividends for Cartesian Therapeutics.

Q

When is Cartesian Therapeutics (NASDAQ:RNAC) reporting earnings?

A

Cartesian Therapeutics does not have any upcoming earnings scheduled.

Q

Is Cartesian Therapeutics (RNAC) going to split?

A

There is no upcoming split for Cartesian Therapeutics.

Q

What sector and industry does Cartesian Therapeutics (RNAC) operate in?

A

Cartesian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.